Abstract
9736 Background: Evaluation of prostate specific antigen (PSA) is the current screening method for early detection of prostate cancer. PSA is more prostate specific than cancer specific, and elevated PSA can also be found in benign conditions of the prostate. Thus, in spite of the overall success of PSA screening, there is a continued need for more sensitive and specific methods for early detection of prostate cancer. Methods: We have developed an antibody-based approach to biomarker discovery in cancer, focusing on differential protein expression, using: i) a large collection of high affinity polyclonal antibodies raised against individual human proteins and their isoforms; ii) a proprietary multiplex protein array immunoassay, namely the matrix protein array technology (MPAT), coupled to a readout and data analysis system, and iii) clinical samples (tissue and serum) from normal, benign prostate hyperplasia (BPH), early and advanced prostate cancer patients. Protein extracts from specimens were printed onto a membrane, then allowed to interact with 20,000 individual antibodies from our collection. Antibody-sample reaction was detected by chemiluminescence, and quantified by computer analysis of a CCD-acquired image, followed by statistical analysis. Results: In the screening of tissue specimens we have identified three distinct panels of antibodies, specific for cancer, BPH and prostate tumor, respectively. In addition, screening of 150 serum samples revealed antibody panels discriminating early versus late stage prostate cancer. We have further characterized these biomarkers by western blot analysis. Conclusions: These biomarkers offer potential applications in the early diagnosis of prostate cancer, and discrimination from benign conditions of the prostate. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Milagen, Inc. Milagen, Inc. Milagen, Inc.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
